Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
3 Dividend Stocks to Buy and Hold for the Next Decade
07:47am, Monday, 28'th Apr 2025
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
02:15pm, Sunday, 27'th Apr 2025
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
07:15pm, Saturday, 26'th Apr 2025
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt�
Tariffs Cast a Shadow on Abbott's 2025 View: Time to Sell ABT Stock?
04:00pm, Friday, 25'th Apr 2025
With certain devices being imported into the United States from overseas, tariff-induced cost pressure is set to rise for Abbott from the third quarter of 2025.
EPD Growth in Emerging Market Supports Abbott Stock Amid Macro Woes
12:40pm, Thursday, 24'th Apr 2025
Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
10:00am, Wednesday, 23'rd Apr 2025
Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
09:58am, Wednesday, 23'rd Apr 2025
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
09:54am, Saturday, 19'th Apr 2025
ABT continues to offer a compelling high-growth investment thesis, driven by the GLP-1 tailwinds on its Continuous Glucose Monitoring and adult nutrition offerings. This is significantly aided by the
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
11:11am, Thursday, 17'th Apr 2025
Abbott Laboratories ABT reported better-than-expected first-quarter adjusted EPS results on Wednesday.
Live: SPDR S&P 500 ETF Trust (SPY) Falls From Nvidia, Trade Pressure
08:00am, Thursday, 17'th Apr 2025
Live Updates Live Coverage Has Ended Gaines and Losers Today 12:59 pm Winners: APA Corp (APA) up 5.27% Abbott Labs (ABT) up 4.37% Devon Energy (DVN) up 4.17% Marathon Petroleum (MPC) up 3.82% Losers:
S&P 500 (NYSEARCA: SPY) Live: JBHT (Nasdaq: JBHT) Falls, ABT (NYSE: ABT) Rises on Tariff Fallout
08:00am, Thursday, 17'th Apr 2025
Live Updates Live Coverage Has Ended S&P Sinks 3% in Tech-Fueled Sell-Off 3:21 pm by Gerelyn Terzo Technology stocks are in freefall mode, sending the S&P 500 to its lows of the session for a
Tariff-Resistant Abbott Laboratories on Track for New Highs
07:37am, Thursday, 17'th Apr 2025
Abbott Laboratories NYSE: ABT is not immune to the impact of tariffs on its medical device business. However, the company's diversified business is tariff-resistant, and moves are being made to streng
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
03:57pm, Wednesday, 16'th Apr 2025
I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth
Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript
11:24am, Wednesday, 16'th Apr 2025
Abbott Laboratories (NYSE:ABT ) Q1 2025 Earnings Conference Call April 16, 2025 9:00 AM ET Company Participants Mike Comilla - VP, IR Robert Ford - Chairman and CEO Phil Boudreau - EVP, Finance and CF
Abbott Laboratories shares gain on first quarter earnings beat
10:43am, Wednesday, 16'th Apr 2025
Abbott Laboratories (NYSE:ABT) reported a profit beat for the first quarter driven by growth in its medical devices and diabetes care segments, as revenue fell short of estimates. The healthcare compa
